ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,713.64
      1.70%
      US Tech 100
      19,304.80
      2.37%
      Dow Jones
      42,025.19
      1.26%
      Brent Oil
      74.115
      -0.28%
      Bitcoin
      63,796.38
      1.35%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE

      6. Amneal Pharmaceuticals Holding Co (AMRX) Quote

      Amneal Pharmaceuticals Holding Co

      Amneal Pharmaceuticals Holding Co (AMRX)

      Amneal Pharmaceuticals Inc
      5.87
      0.00
      (0.00%)
      Closed September 20 4:00PM
      Delayed by 15 minutes
      0.00
      0.00
      (0.00%)
      After Hours: -
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      5.87
      Bid
      -
      Ask
      -
      Volume
      -
      0.00 Day's Range 0.00
      3.36 52 Week Range 5.95
      Market Cap
      1.817B
      Previous Close
      5.87
      Open
      -
      Last Trade
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      -
      Shares Outstanding
      309,542,608
      Dividend Yield
      -
      PE Ratio
      -21.64
      Earnings Per Share (EPS)
      -0.27
      Revenue
      2.41B
      Net Profit
      -83.99M

      About Amneal Pharmaceuticals Holding Co

      Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inha... Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.amneal.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Amneal Pharmaceuticals Holding Co is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker AMRX. The last closing price for Amneal Pharmaceuticals was $5.87. Over the last year, Amneal Pharmaceuticals shares have traded in a share price range of $ 3.36 to $ 5.95.

      Amneal Pharmaceuticals currently has 309,542,608 shares outstanding. The market capitalization of Amneal Pharmaceuticals is $1.82 billion. Amneal Pharmaceuticals has a price to earnings ratio (PE ratio) of -21.64.

      Ask ADVFN Intelligence (AI)

      AMRX Latest News

      More News

      Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration

      Represents Amneal’s fourth 505(b)(2) injectable approval in 2024 Ready-to-use oncology treatment used for multiple myeloma and mantle cell lymphoma Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX...

      September 05 2024
      Business Wire

      Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

      Propofol is an essential surgical anesthetic in hospitals that is in chronic shortage Complex emulsion injectable expands Amneal’s injectables portfolio Amneal Pharmaceuticals, Inc. (Nasdaq:...

      August 20 2024
      Business Wire

      Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

      Propofol is an essential surgical anesthetic in hospitals that is in chronic shortage Complex emulsion injectable expands Amneal’s injectables portfolio Amneal Pharmaceuticals, Inc. (Nasdaq:...

      August 20 2024
      Business Wire

      Form 144 - Report of proposed sale of securities

      August 14 2024
      Edgar (US Regulatory)

      Form 144 - Report of proposed sale of securities

      August 14 2024
      Edgar (US Regulatory)

      UBS Beats Earnings Forecasts, Intel Divests Arm Holdings, Flutter Surges 9% in Premarket Trading, and More

      UBS Group AG (NYSE:UBS) – UBS reported a net profit of $1.136 billion in Q2, exceeding the $528 million forecast. Revenue also surpassed expectations, reaching $11.904 billion. Despite...

      August 14 2024
      IH Market News

      Amneal Reports Second Quarter 2024 Financial Results

      ‒ Q2 2024 Net Revenue of $702 million; GAAP Net Income of $6 million; Diluted Income per Share of $0.02 ‒ ‒ Adjusted EBITDA of $162 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Raising 2024 Full...

      August 09 2024
      Business Wire

      Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

      Delivers more “Good On” time with less frequent dosing compared to Immediate Release CD/LD Underscores Amneal’s leadership in Parkinson’s disease and commitment to one million people currently...

      August 07 2024
      Business Wire

      Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

      First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals...

      July 29 2024
      Business Wire

      Amneal to Report Second Quarter 2024 Results on August 9, 2024

      Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company...

      July 11 2024
      Business Wire
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1005.875.875.8700CS
      4005.875.875.8700CS
      12005.875.875.8700CS
      26005.875.875.8700CS
      521.4833.71298405474.395.953.363739704.37607553CS
      1560.9920.28688524594.885.991.247566253.31655728CS
      2602.5978.96341463413.287.4451.2411087074.05587266CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      MKFGMarkforged Holding Corporation
      $ 2.09
      (16.05%)
      		378.45k
      ASPNAspen Aerogels Inc
      $ 28.77
      (15.64%)
      		2.55M
      TSETrinseo Plc
      $ 4.70
      (15.20%)
      		444.73k
      LICYLi Cycle Holdings Corp
      $ 2.42
      (14.15%)
      		1.92M
      DNMRDanimer Scientific Inc
      $ 0.3899
      (13.61%)
      		799k
      SRFMSurf Air Mobility Inc
      $ 1.12
      (-10.40%)
      		145.92k
      SKXSkechers USA
      $ 61.56
      (-9.62%)
      		9.18M
      HEHawaiian Electric Industries
      $ 10.96
      (-9.12%)
      		6.33M
      STEMStem Inc
      $ 0.4062
      (-9.11%)
      		4.23M
      EVTLVertical Aerospace Ltd
      $ 0.72375
      (-7.73%)
      		937.47k
      NIONIO Inc
      $ 5.39
      (7.37%)
      		93.01M
      PLTRPalantir Technologies Inc
      $ 36.83
      (1.24%)
      		59.88M
      BACBank of America Corporation
      $ 40.87
      (3.15%)
      		57.98M
      FFord Motor Company
      $ 10.9175
      (-0.57%)
      		52.44M
      BBDBanco Bradesco SA
      $ 2.75
      (-0.72%)
      		41.07M

      AMRX Discussion

      View Posts
      Monksdream Monksdream 5 months ago
      AMRX under $10
      👍️0
      Monksdream Monksdream 6 months ago
      AMRX under $10
      👍️0
      Luckypennyman Luckypennyman 2 years ago
      Amarin Announces New REDUCE-IT® Data. March 5, 2023.

      DUBLIN, Ireland and BRIDGEWATER, N.J., March 05, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a new analysis from the VASCEPA/VAZKEPA (icosapent ethyl) cardiovascular outcomes REDUCE-IT study showing the effectiveness of VASCEPA®/VAZKEPA® in patients with recent acute coronary syndrome (<12 months before randomization). This post-hoc analysis showed that icosapent ethyl (IPE) substantially and significantly reduced the risk of first and total ischemic events by 37% and 36% respectively in patients with recent acute coronary syndrome (ACS) without increasing bleeding, supporting early initiation of IPE after ACS. The data were presented at the American College of Cardiology’s 72nd Annual Scientific Session together with the World Heart Federation’s World Congress of Cardiology in New Orleans, LA.

      https://healthstockshub.com/news/nasdaq/amrn/amarin-announces-new-reduce-it-data-at-acc-23-wcc-showing-benefit-of-vascepa-vazkepa-icosapent-ethyl-in-high-risk-patients-with-a-recent-acute-coronary-syndrome-event
      👍️0
      Jake L Jake L 3 years ago
      AMRX - Update

      👍️0
      TrendTrade2016 TrendTrade2016 4 years ago
      monster bio beast ready to beast in beast land!!
      👍️0
      ClayTrader ClayTrader 4 years ago
      * * $AMRX Video Chart 03-08-2021 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      ListenToMe ListenToMe 4 years ago
      AMRX is a good long term hold.
      👍️0
      ListenToMe ListenToMe 4 years ago
      I was hoping AMRX would have better news
      👍️0
      ListenToMe ListenToMe 4 years ago
      Any opinions on AMRX for 2021?
      👍️0
      ListenToMe ListenToMe 4 years ago
      AMRX... the time will come.!
      👍️0
      ListenToMe ListenToMe 4 years ago
      Looks like amrx is going into the 3's
      👍️0
      ListenToMe ListenToMe 4 years ago
      I agree AMRX needs a good catalyst to bring some well deserved attention to this company!

      AMRX has huge potential!!
      👍️0
      Elpapibh Elpapibh 4 years ago
      It’s a fantastic play, it’s just they’re in the background and no demand for shares can keep this where it’s at
      👍️0
      ListenToMe ListenToMe 4 years ago
      I'm still thinking AMRX will be a great Sleeper play!!
      👍️0
      ListenToMe ListenToMe 4 years ago
      AMRX is getting a little bounce today. nice
      👍️0
      Elpapibh Elpapibh 4 years ago
      No demand, yet
      👍️0
      ListenToMe ListenToMe 4 years ago
      I'm really surprised this thing isn't 4X Higher.

      AMRX
      👍️0
      Elpapibh Elpapibh 4 years ago
      Close to 2 bil market cap no reason for such a dip. Let’s see how the re-recovery looks.
      👍️0
      Elpapibh Elpapibh 4 years ago
      Let’s see what these earnings dooo
      👍️0
      Elpapibh Elpapibh 4 years ago
      Another snack of a close.!! Who’s riding this wave with me???
      👍️0
      Elpapibh Elpapibh 4 years ago
      Fantastic close...
      👍️0
      Elpapibh Elpapibh 4 years ago
      Did I jump on the train too late? I think not. Why isn’t this company forum more popping?
      👍️0
      ListenToMe ListenToMe 4 years ago
      AMRX could be a doubler by end of year!
      👍️0
      ListenToMe ListenToMe 4 years ago
      Amneal is a solid company and will pay off big.
      👍️0
      Bngo Bngo 4 years ago
      With President Trump trying to bring API manufacturing back to The USA to help us rely less on China and India, hopefully all US drug manufacturers can all benefit from this move including Amneal.

      Here is a good reason why Amneal is a great candidate for long term success.

      https://investors.amneal.com/news/press-releases/press-release-details/2019/Amneal-to-Acquire-Majority-Interest-in-AvKARE-Enhancing-Access-to-Growing-Federal-Healthcare-Market/default.aspx
      👍️0
      dangerx dangerx 4 years ago
      Nice week AMRX ??
      👍️0
      dangerx dangerx 4 years ago
      Shorts and scares. Plus the whole generic pharmaceutical market has been in the crapper for years. Amneal has done great things during that time like launching high value generics and acquiring valuable manufacturers and distributors. It’s only a matter of time before their NDAs and bioequivalents start being major profit centers. Glad you’re on board with this little pharmaceutical company that could (and has!)
      👍️0
      ListenToMe ListenToMe 4 years ago
      I agree AMRX is a big Winner!!
      👍️0
      Bngo Bngo 4 years ago
      This should be a good reason why Amneal is a great candidate for long term success.


      https://investors.amneal.com/news/press-releases/press-release-details/2019/Amneal-to-Acquire-Majority-Interest-in-AvKARE-Enhancing-Access-to-Growing-Federal-Healthcare-Market/default.aspx
      👍️0
      Bngo Bngo 4 years ago
      I like the company with its promising government contract, but why are we still so far away from $182?
      👍️0
      ListenToMe ListenToMe 4 years ago
      AMRX is my fav. Pharma play.
      👍️0
      ListenToMe ListenToMe 4 years ago
      AMRX ... buy the dip.
      Very solid company.
      👍️0
      ListenToMe ListenToMe 4 years ago
      AMRX is a GREAT long-term play.
      Many drugs in the pipeline, sales have been consistently increasing and its a US manufacturer.

      WIN WIN WIN


      AMRX
      👍️0
      ListenToMe ListenToMe 4 years ago
      AMRX has huge potential. Positioned perfectly to capitalize on the rebirth of US drugs!
      👍️0
      dangerx dangerx 4 years ago
      I think institutional investors might come to play too. I’m pretty sure it was over 90% last year and now 69% according to schwab. If that number grows I’ll have 0 worries here.
      👍️0
      ListenToMe ListenToMe 4 years ago
      #FACT...$182 was the price target last year for AMRX. From at least TWO (2) major analysts.


      AMRX = Big $$$$

      👍️0
      ListenToMe ListenToMe 4 years ago
      As I was saying... AMRX is quietly laying the groundwork for significant developments!$$$


      AMRX = Extremely Strong BUY$$$$....



      BOOM
      👍️0
      ListenToMe ListenToMe 4 years ago
      AMRX is just cruising along and laying low right now...BUT the day of recognition is coming!!$$

      And it will be one of the Most talked about companies in the world ??!$$$

      AMRX
      👍️0
      ListenToMe ListenToMe 4 years ago
      Now you're talking!!
      I like the sound of that.

      AMRX is Awesome!!!
      👍️0
      dangerx dangerx 4 years ago
      Shorts cover, approval for biosimilar meds, or Kodak’s grant gets cancelled and goes to AMRX instead.

      I’d be happy with a short squeeze.
      👍️0
      ListenToMe ListenToMe 4 years ago
      So I'm trying to figure out what would be a great catalyst to make AMRX surge to the next level above $20.00 range.

      Hmmmmm
      👍️0
      ListenToMe ListenToMe 4 years ago
      Lots of interest in AMRX.
      👍️0
      dangerx dangerx 4 years ago
      Things haven’t even got going yet... This is just the tap water in the pot when you first turn on the burner.
      👍️0
      ListenToMe ListenToMe 4 years ago
      And.... HERE WE GO!!$$$

      amrx
      👍️0
      ListenToMe ListenToMe 4 years ago
      Looking Very Strong!!

      AMRX
      👍️0
      ListenToMe ListenToMe 4 years ago
      Can't go wrong with AMRX!!!
      👍️0
      ListenToMe ListenToMe 4 years ago
      Can't go wrong with AMRX!!!
      👍️0
      ListenToMe ListenToMe 4 years ago
      AMRX... $5.00 - $10.00 - $50.00 - $100+ !!!$$$$
      👍️0
      ListenToMe ListenToMe 4 years ago
      $182 was the price target last year for AMRX. From TWO major analysts.
      👍️0
      ListenToMe ListenToMe 4 years ago
      Insiders are loading AMRX.

      Value buyers are buying.

      AMRX IS the Most undervalued pharma stock .
      👍️0

      Your Recent History

      NYSE
      AMRX
      Amneal Pharmaceuticals
      Delayed Upgrade Clock